601607 上海医药
交易中 08-01 14:50:32
资讯
新帖
简况
业绩失守、三期款悬停、对赌压顶，上药罗欣价值重估已“箭在弦上”？
钛媒体APP · 01:56
业绩失守、三期款悬停、对赌压顶，上药罗欣价值重估已“箭在弦上”？
上海医药：公司抗生素相关业务归类为抗感染类，已在年报中进行披露
互动易 · 07-31 07:33
上海医药：公司抗生素相关业务归类为抗感染类，已在年报中进行披露
医药上市公司财务总监PK：迈瑞医疗CFO年薪登顶 *ST四环29岁CFO任职不满一年即离职
新浪证券 · 07-31 01:55
医药上市公司财务总监PK：迈瑞医疗CFO年薪登顶 *ST四环29岁CFO任职不满一年即离职
SPD(医疗供应链管理)概念盘中拉升，柳药集团涨3.97%
市场透视 · 07-30 02:26
SPD(医疗供应链管理)概念盘中拉升，柳药集团涨3.97%
2025年，全球医药行业迎来新一轮研发管线大调整！
制药网 · 07-29
2025年，全球医药行业迎来新一轮研发管线大调整！
第一医药涨5.05% 上海医药政策红利吸引游资叠加估值优势资金博弈
智选洞察 · 07-29
第一医药涨5.05% 上海医药政策红利吸引游资叠加估值优势资金博弈
上海医药(02607.HK)：硫酸沙丁胺醇注射液通过仿制药一致性评价
智通财经 · 07-28
上海医药(02607.HK)：硫酸沙丁胺醇注射液通过仿制药一致性评价
上海医药(601607.SH)：硫酸沙丁胺醇注射液通过仿制药一致性评价
智通财经 · 07-28
上海医药(601607.SH)：硫酸沙丁胺醇注射液通过仿制药一致性评价
每周股票复盘：上海医药（601607）拟1.43亿收购上实财务10%股权
证券之星 · 07-26
每周股票复盘：上海医药（601607）拟1.43亿收购上实财务10%股权
上海医药(02607.HK)拟斥资约1.43亿元收购财务公司 10%股权
智通财经 · 07-25
上海医药(02607.HK)拟斥资约1.43亿元收购财务公司 10%股权
上海医药：拟1.43亿元收购财务公司10%股权
格隆汇 · 07-25
上海医药：拟1.43亿元收购财务公司10%股权
中证全指食品与主要用品零售指数报9779.92点，前十大权重包含益丰药房等
金融界 · 07-24
中证全指食品与主要用品零售指数报9779.92点，前十大权重包含益丰药房等
华润山东医药等六公司中标东营市人民医院药品配送项目
DoNews · 07-24
华润山东医药等六公司中标东营市人民医院药品配送项目
熊去氧胆酸概念盘中拉升，广生堂涨2.64%
市场透视 · 07-23
熊去氧胆酸概念盘中拉升，广生堂涨2.64%
上海医药：氨甲环酸注射液通过仿制药一致性评价
格隆汇 · 07-21
上海医药：氨甲环酸注射液通过仿制药一致性评价
单抗概念盘中拉升，奥赛康涨3.37%
市场透视 · 07-21
单抗概念盘中拉升，奥赛康涨3.37%
老牌药企的人效薪酬战略：华东、复星、上药
药事纵横 · 07-17
老牌药企的人效薪酬战略：华东、复星、上药
大摩：升上海医药(02607)目标价至18港元 评级“增持”
智通财经 · 07-17
大摩：升上海医药(02607)目标价至18港元 评级“增持”
融合·协同·赋能！上实集团董事长冷伟青调研上海医药旗下上海和黄药业
上海医药 · 07-16
融合·协同·赋能！上实集团董事长冷伟青调研上海医药旗下上海和黄药业
医药生物板块复苏，部分药企业绩大幅增长
制药网 · 07-15
医药生物板块复苏，部分药企业绩大幅增长
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。公司荣获2024《财富》世界500强、2024全球制药企业50强等荣誉。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":19.29,"timestamp":1754031032000,"preClose":19.04,"halted":0,"volume":17921065,"delay":0,"changeRate":0.0131,"floatShares":2789000000,"shares":3708000000,"eps":1.1713,"marketStatus":"交易中","change":0.25,"latestTime":"08-01 14:50:32","open":19.12,"high":19.58,"low":19.06,"amount":347000000,"amplitude":0.0273,"askPrice":19.29,"askSize":161,"bidPrice":19.28,"bidSize":154,"shortable":0,"etf":0,"ttmEps":1.1713,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1754031600000},"marketStatusCode":2,"adr":0,"adjPreClose":19.04,"symbolType":"stock","openAndCloseTimeList":[[1754011800000,1754019000000],[1754024400000,1754031600000]],"highLimit":20.94,"lowLimit":17.14,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.97,"roa":"--","peRate":16.468881,"roe":"1.84%","epsLYR":1.23,"committee":0.283057,"marketValue":71534000000,"turnoverRate":0.0064,"status":0,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":12.52,"timestamp":1754031033383,"preClose":12.54,"halted":0,"volume":2562500,"delay":0,"premium":"-40.33"},"floatMarketCap":53804000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2556868412","title":"业绩失守、三期款悬停、对赌压顶，上药罗欣价值重估已“箭在弦上”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2556868412","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556868412?lang=zh_cn&edition=full","pubTime":"2025-08-01 09:56","pubTimestamp":1754013369,"startTime":"0","endTime":"0","summary":"待到三年业绩对赌期限届满，上药山东对上药罗欣重新估值的“大考时刻”来临，交易受让方很可能走上“止损”之路。三年业绩对赌，等待上药罗欣的或是价值重估未依据业绩完成比例按时支付转让款，上药山东或许已经在慎重考虑，是否要在三年业绩承诺期结束后，对上药罗欣进行重新估值。此次股权转让截至2023年2月已完成交割，上药罗欣不再纳入罗欣药业合并报表范围内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801095858a6ccb4d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801095858a6ccb4d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0187","SHPMY","601607","02607","BK0020","BK0196","BK0099","BK0028","BK0175","BK0209","BK0188","BK0012","BK0097","BK0184","BK0183"],"gpt_icon":0},{"id":"2555000149","title":"上海医药：公司抗生素相关业务归类为抗感染类，已在年报中进行披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2555000149","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555000149?lang=zh_cn&edition=full","pubTime":"2025-07-31 15:33","pubTimestamp":1753947188,"startTime":"0","endTime":"0","summary":"有投资者向上海医药提问， 贵公司是否涉及抗生素相关业务？如果是，为何未见在年报和ESG报告中披露抗生素管理相关信息，后续是否有计划在年报及ESG报告中披露具体的抗生素管理风险与机遇？公司回答表示，尊敬的投资者您好，公司抗生素相关业务归类为抗感染类，已在年报中进行披露。感谢您的关注与支持！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073115540194c5a237&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073115540194c5a237&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0099","BK0184","BK0209","BK0187","BK0020","BK0196","601607","BK0183","BK0028","BK0097","BK0012","BK0188","BK0175"],"gpt_icon":0},{"id":"2555079782","title":"医药上市公司财务总监PK：迈瑞医疗CFO年薪登顶 *ST四环29岁CFO任职不满一年即离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2555079782","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555079782?lang=zh_cn&edition=full","pubTime":"2025-07-31 09:55","pubTimestamp":1753926900,"startTime":"0","endTime":"0","summary":"新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为81.48万元。分行业来看，统计数据显示，A股共有494家上市医药生物公司，CFO聘任总体情况如下。其中，赵洁于2024年4月担任*ST四环CFO，后于今年6月离职。其中，除迈瑞医疗的赵云之外，其余三名CFO均在公司兼任其他职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507310956379728f669&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507310956379728f669&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0031814852.USD","LU0405327494.USD","LU2424517915.HKD","LU0650527681.SGD","LU1023057109.AUD","LU1781817850.SGD","LU1146622755.USD","IE00B29SXG58.USD","02607","LU0084288322.USD","LU0594300179.USD","LU1794554557.SGD","159938","LU1734074674.USD","LU1934453819.USD","BK0046","LU1979443071.USD","LU0823426308.USD","LU0359201612.USD","LU0359202008.SGD","LU0572944931.SGD","LU0405327148.USD","LU2348774022.SGD","LU0605514214.HKD","LU1064130708.USD","LU2153592121.USD","LU1064131003.USD","LU1720050803.USD","SHPMY","LU2488822045.USD","BK0239","BK0086","IE0008368742.USD","BK0251","000518","LU1820825898.SGD","LU1997245177.USD","LU0594300419.USD","SGXZ81163826.USD","LU2213484517.USD","688192","IE00B031J352.USD","IE0005HP3H50.USD","SGXZ49509284.SGD","601607","LU2348773727.SGD","300760","IE00B031HY20.USD","BK0168","LU0327786744.USD","LU0823426480.USD","LU1655091616.SGD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2555323096","title":"SPD(医疗供应链管理)概念盘中拉升，柳药集团涨3.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555323096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555323096?lang=zh_cn&edition=full","pubTime":"2025-07-30 10:26","pubTimestamp":1753842398,"startTime":"0","endTime":"0","summary":"07月30日，SPD(医疗供应链管理)概念盘中拉升，截至10点26分，SPD(医疗供应链管理)概念整体指数上涨1.04%，报1326.210点。从个股上来看，该概念的成分股中，柳药集团涨3.97%，畅联股份、红日药业、上海医药涨幅居前。从资金上来看，截止发稿，SPD(医疗供应链管理)概念主力净流入为-199.91万，其中柳药集团受到资金热捧，主力净流入1741.75万；拉长时间线来看，该板块近20日主力资金净流入-11.70亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073010263894c2d0f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073010263894c2d0f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603368","BK0070","601607","02607","159891","BK0250","SHPMY","603648"],"gpt_icon":0},{"id":"2555896510","title":"2025年，全球医药行业迎来新一轮研发管线大调整！","url":"https://stock-news.laohu8.com/highlight/detail?id=2555896510","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555896510?lang=zh_cn&edition=full","pubTime":"2025-07-29 11:23","pubTimestamp":1753759427,"startTime":"0","endTime":"0","summary":" 2025年，全球医药行业又迎来了新一轮研发管线调整，大批药物开发项目被终止，涉及肿瘤、代谢疾病、中枢神经系统等多个领域，以及罗氏、辉瑞、强生、上海医药等众多国内外药企。近日，罗氏发布了2025年半年报，同时宣布砍掉7大研发管线，包括四项I期和三项III期临床研究。截至2025年6月30日，原料药项目累计投入募集资金1.79亿元，剩余募集资金2.16亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072911262494c097b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072911262494c097b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0099","BK0175","BK0012","BK0209","BK0097","BK0187","601607","BK0196","BK0020","BK0188","SHPMY","BK0028","BK0184","02607","PFE","688550"],"gpt_icon":0},{"id":"2555964086","title":"第一医药涨5.05% 上海医药政策红利吸引游资叠加估值优势资金博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=2555964086","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555964086?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:47","pubTimestamp":1753757247,"startTime":"0","endTime":"0","summary":"第一医药股价大幅上涨，最新价13.74元，涨跌幅为5.05%。上海医药流通政策红利带来的题材效应吸引游资参与，但机构对2025年上半年净利润同比预降87.8%-90.3%的业绩预告保持谨慎，形成资金分歧。当前23.27倍动态市盈率较行业中枢存在折价，部分左侧资金借估值优势入场布局，加剧股价波动弹性。区域深耕与经营韧性构建价值锚点从长期维度观察，第一医药在上海市场的渠道优势持续强化经营壁垒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729104733a6c6ebf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729104733a6c6ebf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0188","BK0020","BK0184","601607","BK0028","BK0187","600833","BK0196","BK0175","BK0099","BK0012","BK0209","BK0097"],"gpt_icon":0},{"id":"2554720181","title":"上海医药(02607.HK)：硫酸沙丁胺醇注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2554720181","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554720181?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:06","pubTimestamp":1753697213,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0209","BK0012","01477","601607","BK0020","BK0187","BK0188","BK0196","BK1574","BK0175","BK0099","BK0028","BK1191","BK1197","BK0184","BK0097","02607","BK0183"],"gpt_icon":0},{"id":"2554353724","title":"上海医药(601607.SH)：硫酸沙丁胺醇注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2554353724","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554353724?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:56","pubTimestamp":1753692963,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海禾丰制药有限公司(以下简称“上药禾丰”)的硫酸沙丁胺醇注射液收到国家药品监督管理局(“国家药监局”)颁发的《药品补充申请批准通知书》(通知书编号：2025B03280)，该药品通过仿制药质量和疗效一致性评价。根据国家相关政策，通过一致性评价的品种在医保支付及医疗机构采购等领域将获得更大的支持力度。因此上药禾丰的硫酸沙丁胺醇注射液通过仿制药一致性评价，有利于扩大该药品的市场份额，提升市场竞争力，同时为公司后续产品开展一致性评价工作积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0012","BK0188","BK0020","601607","BK0187","BK0196","BK0175","BK0099","BK0028","BK1197","BK0184","BK0097","02607","BK0183"],"gpt_icon":0},{"id":"2554736714","title":"每周股票复盘：上海医药（601607）拟1.43亿收购上实财务10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2554736714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554736714?lang=zh_cn&edition=full","pubTime":"2025-07-27 06:15","pubTimestamp":1753568117,"startTime":"0","endTime":"0","summary":"截至2025年7月25日收盘，上海医药报收于18.98元，较上周的18.98元上涨0.0%。本周，上海医药7月23日盘中最高价报19.35元。财务公司2024年度资产总额117.16亿元，负债总额102.85亿元，净资产14.31亿元，营业收入1.31亿元，净利润6054.53万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072700001128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","601607","BK0020","BK0097","BK0196","BK0099","BK1197","BK0187","BK0184","BK0012","BK0188","BK0209","BK0175","02607"],"gpt_icon":0},{"id":"2554767713","title":"上海医药(02607.HK)拟斥资约1.43亿元收购财务公司 10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2554767713","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554767713?lang=zh_cn&edition=full","pubTime":"2025-07-25 20:44","pubTimestamp":1753447467,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0196","BK0012","BK0099","BK0184","BK0028","CNHmain","MCNHmain","BK0175","601607","BK0187","BK0188","BK0183","BK0020","UCmain","02607","BK1197","BK0209","MUCmain","BK0097","CYB"],"gpt_icon":0},{"id":"2554653257","title":"上海医药：拟1.43亿元收购财务公司10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2554653257","media":"格隆汇","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554653257?lang=zh_cn&edition=full","pubTime":"2025-07-25 17:51","pubTimestamp":1753437073,"startTime":"0","endTime":"0","summary":"格隆汇7月25日丨上海医药(601607.SH)公布，公司拟以自有资金约人民币1.43亿元（以最终国资备案价格为准）收购上海实业东滩投资开发（集团）有限公司（简称“上实东滩”）持有的上海上实集团财务有限公司（简称“财务公司”或“标的公司”）10%股权。本次交易完成后，公司持有财务公司的股权比例由30%增加至40%，不会导致公司合并报表范围发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072517512394ba4ad1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072517512394ba4ad1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02607","601607","BK0097","BK0209","BK0175","BK0012","BK0187","BK0028","BK0188","BK0184","SHPMY","BK0020","BK0183","BK0099","BK0196"],"gpt_icon":0},{"id":"2553020815","title":"中证全指食品与主要用品零售指数报9779.92点，前十大权重包含益丰药房等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553020815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553020815?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:18","pubTimestamp":1753345092,"startTime":"0","endTime":"0","summary":"数据统计显示，中证全指食品与主要用品零售指数近一个月上涨4.43%，近三个月上涨0.49%，年至今下跌3.88%。据了解，中证全指食品与主要用品零售指数从中证全指指数中选取与食药零售主题相对应的行业内上市公司证券作为指数样本，以反映该主题上市公司证券的整体表现。从中证全指食品与主要用品零售指数持仓样本的行业来看，医药商业占比44.64%、超市与便利店占比20.60%、专营零售占比20.32%、百货商店占比14.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072416250394b7dbf3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072416250394b7dbf3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601933","600859","600998","600511","BK4175","603939","601607","02607","SHPMY"],"gpt_icon":0},{"id":"2553276150","title":"华润山东医药等六公司中标东营市人民医院药品配送项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276150","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553276150?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:34","pubTimestamp":1753335243,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年07月23日，东营市人民医院发布药品集中配送服务商遴选招标项目中标结果公告。此次招标由东营市人民医院发起，最终确定的中标供应商包括华润山东医药有限公司、瑞康医药集团股份有限公司、上药控股东营有限公司、山东康诺盛世医药有限公司、国药控股东营有限公司以及东营九州通医药有限公司。本次公告类型为中标结果公告，项目代理机构为山东金卫医药信息有限公司。公告期限为自发布之日起1个工作日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413344594b79206&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413344594b79206&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0516422366.SGD","LU0370786039.SGD","LU0516423174.USD","LU1242518857.USD","LU0067412154.USD","LU0417516902.SGD","LU0516422952.EUR","LU0516422440.USD","SG9999010052.SGD","LU1807302812.USD","LU0359201612.USD","LU0791590937.USD","LU2088747725.USD","BK1589","BK1240","SG9999010078.USD","BK1570","SHPMY","601607","LU0594300419.USD","LU0791591158.USD","LU1366334651.USD","LU0359202008.SGD","LU2088747998.USD","SG9999009997.SGD","LU0414403682.SGD","02607","LU0605514214.HKD","LU1152091754.HKD","LU0348825331.USD","LU0594300179.USD","03320","LU1008478684.HKD","LU0501845795.SGD","BK1521","01099","09939","LU0880133367.SGD","SHTDY","BK1574","LU0650527681.SGD","LU1993786604.SGD","LU0516423091.SGD","LU1242518931.SGD","LU0173614495.USD","LU1023057109.AUD","LU2088748020.USD","LU0048580855.USD","LU1366334578.USD","LU0048597586.USD","01109","LU0251144936.SGD","LU0979878070.USD","LU1960683339.HKD","IE0008368742.USD","LU0287142896.SGD"],"gpt_icon":0},{"id":"2553673892","title":"熊去氧胆酸概念盘中拉升，广生堂涨2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553673892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553673892?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:40","pubTimestamp":1753234812,"startTime":"0","endTime":"0","summary":"07月23日，熊去氧胆酸概念盘中拉升，截至09点40分，熊去氧胆酸概念整体指数上涨0.54%，报1352.250点。从个股上来看，该概念的成分股中，广生堂涨2.64%，上海医药、华润双鹤、人福医药涨幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-4744.77万，其中千红制药受到资金热捧，主力净流入1282.67万；拉长时间线来看，该板块近20日主力资金净流入-19.15亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723094012954dd1f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723094012954dd1f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0012","600079","BK0096","BK0185","BK0028","SHPMY","601607","BK0070","300436","BK0239","02607"],"gpt_icon":0},{"id":"2553424911","title":"上海医药：氨甲环酸注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2553424911","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553424911?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:15","pubTimestamp":1753085736,"startTime":"0","endTime":"0","summary":"格隆汇7月21日丨上海医药(601607.SH)公布，下属上海信谊金朱药业有限公司（简称“信谊金朱”）的氨甲环酸注射液收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。氨甲环酸注射液主要用于急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致的各种出血。弥散性血管内凝血所致的继发性高纤溶状态，在未肝素化前，一般不用本品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721161543954ab7c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721161543954ab7c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0097","BK0184","BK0183","BK0209","BK0020","BK0196","BK0028","BK0188","BK0012","BK0175","601607","BK0187","BK0099"],"gpt_icon":0},{"id":"2553270442","title":"单抗概念盘中拉升，奥赛康涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553270442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553270442?lang=zh_cn&edition=full","pubTime":"2025-07-21 09:41","pubTimestamp":1753062090,"startTime":"0","endTime":"0","summary":"07月21日，单抗概念盘中拉升，截至09点41分，单抗概念整体指数上涨0.51%，报2647.070点。从个股上来看，该概念的成分股中，奥赛康涨3.37%，贝达药业、海普瑞、上海医药涨幅居前。从资金上来看，截止发稿，单抗概念概念主力净流入为-1315.00万，其中奥赛康受到资金热捧，主力净流入3813.52万；拉长时间线来看，该板块近20日主力资金净流入18.20亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721094130a457f036&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721094130a457f036&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4175","09989","601607","02607","SHPMY"],"gpt_icon":0},{"id":"2552488664","title":"老牌药企的人效薪酬战略：华东、复星、上药","url":"https://stock-news.laohu8.com/highlight/detail?id=2552488664","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552488664?lang=zh_cn&edition=full","pubTime":"2025-07-17 17:00","pubTimestamp":1752742800,"startTime":"0","endTime":"0","summary":"华东医药深耕内分泌、自身免疫及肿瘤等治疗领域，持续加大研发投入，不断丰富创新药研发管线布局。图：华东医药 研发管线布局从企业规模来看，复星医药和上海医药都是4万+总员工数，其中上海医药更是直逼5万员工总数大关。华东医药相比而言企业规模稍小，近不到2万人，但是从研发人员占比来看，华东医药毫不逊色，其研发员工人员1864名，研发人员占比12.44%，比复星医药的7.51%高5%左右，是上海医药3.59%研发人员占比的3倍多。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717180448a450d463&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717180448a450d463&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601607","BK0020","600196","BK0012","BK0099","BK0175","BK0184","BK0188","BK0209","BK0196","BK0097","BK0187","BK0028","BK0183"],"gpt_icon":0},{"id":"2552057291","title":"大摩：升上海医药(02607)目标价至18港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552057291","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552057291?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:43","pubTimestamp":1752734628,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，对上海医药(02607)目标价由17港元升至18港元，相当于预测2026年市盈率9.7倍，评级“增持”。考虑到中期业绩盈喜，该行将上海医药2025至2030年的盈利预测上调1至11%，原因是分销和制造业务的销售额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607"],"gpt_icon":0},{"id":"2551919117","title":"融合·协同·赋能！上实集团董事长冷伟青调研上海医药旗下上海和黄药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2551919117","media":"上海医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551919117?lang=zh_cn&edition=full","pubTime":"2025-07-16 14:08","pubTimestamp":1752646100,"startTime":"0","endTime":"0","summary":"7月14日下午，上实集团董事长冷伟青一行赴上海医药旗下上海和黄药业有限公司调研，深入了解和黄药业正式纳入上海医药体系后业务融合发展情况和关键任务推进落实情况，并围绕赋能加速中药整体业务发展，开展座谈交流。上实集团副总裁、上海医药董事长杨秋华，上海医药执行董事、总裁沈波等陪同调研。冷伟青充分肯定和黄药业团队展现出的自驱力、凝聚力和核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716141644a44df5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716141644a44df5f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["561510","562390","BK0097","BK0209","BK0028","BK0187","BK0175","BK0183","BK0184","BK0188","601607","BK0196","BK0012","BK0099","BK0020"],"gpt_icon":0},{"id":"2551305061","title":"医药生物板块复苏，部分药企业绩大幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2551305061","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551305061?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:33","pubTimestamp":1752546781,"startTime":"0","endTime":"0","summary":"在众多行业中，医药生物板块迎来复苏迹象，药明康德、上海医药、甘李药业等企业业绩表现亮眼，呈现大幅增长态势。甘李药业表示，业绩预增主要受益于营业收入的显著提升及公司费用的精细化管控。医药生物板块的复苏，一方面得益于企业自身的业务拓展、成本控制和研发成果转化，另一方面也反映出市场对医药行业的信心逐步恢复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151034519542dbc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151034519542dbc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","163118","BK0097","BK0183","BK0175","603259","BK0012","BK0196","BK0209","BK0028","BK0187","601607","603087","BK0184","000808.SH","BK0099","BK0020"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1754031037816,"stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":0.0831},{"period":"3month","weight":0.0764},{"period":"6month","weight":-0.0405},{"period":"1year","weight":0.0009},{"period":"ytd","weight":-0.0794}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":0.0334},{"period":"3month","weight":0.0897},{"period":"6month","weight":0.0992},{"period":"1year","weight":0.2159},{"period":"ytd","weight":0.0661}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"78411人(较上一季度增加Infinity%)","perCapita":"35571股","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。公司荣获2024《财富》世界500强、2024全球制药企业50强等荣誉。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}